Bionano Genomics, Inc. Common Stock
BNGOBionano Genomics, Inc. is a biotechnology company specializing in genome analysis, primarily through its optical genome mapping technology. The company's platform enables researchers and clinicians to detect structural variations in DNA with high resolution, facilitating insights into genetic diseases, cancer, and complex genetic disorders. Bionano's technologies are used in research, medical diagnostics, and agrigenomics to improve understanding of genomic structure and variation.
Company News
Bionano Genomics completed a public offering of 5 million shares and warrants, raising approximately $10 million gross proceeds to be used for working capital and general corporate purposes.
Bionano Genomics has priced a public offering of 5 million shares and accompanying warrants at $2.00 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.
Bionano Genomics announced a $10 million registered direct offering, with the proceeds to be used for general corporate purposes. The offering includes the sale of common stock and warrants to institutional investors.
Bionano Genomics announced an amendment to its senior secured convertible debentures, which defers near-term debt payments and reduces cash needs, strengthening the company's capital structure and improving its near-term liquidity position.
Bionano Genomics expects lower-than-expected revenue for Q3 2024, citing a strategic shift in the business and continued headwinds in the tools and diagnostics sector. The company remains focused on driving utilization and adoption of its optical genome mapping (OGM) technology from its existing installed base.
